
Opinion|Videos|May 16, 2024
Collaborating with Other Care Providers to Optimize Outcomes for Patients Receiving Bispecifics
The expert panel explores the importance of communication and collaboration among care providers when patients with multiple myeloma who are receiving treatment with bispecific antibodies navigate transitions of care to and from various healthcare settings.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA, HHS Move to Accelerate Biosimilar Approvals
2
Accelerated Approval of Cancer Drugs: Benefit or Burden?
3
COVID-19 mRNA Vaccines May Boost Immunotherapy Response in Cancer
4
Pharmacists Lead the Way in Evolving CAR T-Cell and Bispecific Antibody Therapy Management
5




















































































































































































































